Arena's CB2 agonist will likely get fast tracked for approval by the FDA once the trials are completed.
From this weeks NEJM editorial:
Chronic Pain, Addiction, and Zohydro
Yngvild Olsen, M.D., M.P.H., and Joshua M. Sharfstein, M.D.
April 23, 2014DOI: 10.1056 NEJM1404181
Chronic pain, which affects tens of millions of people in the United States, is associated with functional loss and disability, reduced quality of life, high health care costs, and premature death. U.S. physicians are now more likely to recognize and treat chronic pain than they have been historically, with the number of prescriptions written for opioids having increased 10-fold since 1990.
Over the same period, however, the rate of overdose deaths in the United States has more than tripled.
The following two statements are key for Arena for both belviq and CB2 agonists:
It is also time for the FDA to address the intertwining of chronic pain and addiction farther upstream in the drug-development cycle (fast tracking of CB2 agonist)
The agency might consider creating a pathway for development and review of new products and indications for simultaneous treatment of chronic pain and opioid-use disorder. (Lorcaserin has demonstrated potential for treatment of substance abuse).
Just food for thought – however, these are very real possibilities because the basic science has been mastered by Arena and now we await the completion of making this science work for the benefit of our patients.
The huge potential of CB2 agonists in the treatment of chronic pain has not been fully appreciated.
Sentiment: Strong Buy
APD371 was allways my pibeline favorit. I hope we will soon hear more from the current ongoing phase 1 study. But i think we will need a positive phase 2 study before WS will give this drug any valuation. The finiacial potential of this drug candidate is allmost unlimited. People in generel will pay any price do anything to buy a drug to help against chronic pain( wich is safe and non addictive) and doctors all over the world need a new group of painkillers.
Thank for all your contributions Dr dan.
Sentiment: Strong Buy